<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356040</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10303</org_study_id>
    <secondary_id>CRD_978</secondary_id>
    <nct_id>NCT04356040</nct_id>
  </id_info>
  <brief_title>TactiFlex AF IDE Trial</brief_title>
  <official_title>Safety and Effectiveness of TactiFlex™ Ablation Catheter, Sensor Enabled™ (TactiFlex SE) for the Treatment of Drug Refractory, Symptomatic, Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized multi-center clinical investigation. Design includes a main study&#xD;
      and a separate substudy. Subjects in the main study are to be treated using the full range of&#xD;
      ablation power settings in the IFU. Subjects in the substudy are to be treated in the upper&#xD;
      end of the recommended ablation power settings (40-50 Watts).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is intended to demonstrate the safety and effectiveness of the&#xD;
      TactiFlexTM Ablation Catheter, Sensor EnabledTM (TactiFlex SE) for treating symptomatic&#xD;
      drug-refractory paroxysmal atrial fibrillation. This clinical investigation will be conducted&#xD;
      under an investigational device exemption (IDE) and is intended to support market approval of&#xD;
      the TactiFlex SE catheter worldwide. Three hundred fifty-five (355) subjects will be enrolled&#xD;
      at up to 50 investigational sites worldwide. This clinical investigation is sponsored by&#xD;
      Abbott.&#xD;
&#xD;
      The TactiFlex IDE Clinical Study will enroll a total of 355 subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, non-randomized, multi-center pivotal clinical trial to evaluate the safety and effectiveness of ablation with the TactiFlex SE catheter for the treatment of PAF compared to pre-determined performance goals. The study design includes a substudy to assure that there will be a statistically sufficient number of subjects ablated at the high-end of the ablation power setting recommendations in the investigational Instructions for Use document. Subjects in the HSP (High Standard Power) substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power. Subjects will be enrolled in either the main study or the substudy at the point of consent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Device or Procedure-related Serious Adverse Events</measure>
    <time_frame>Through 12 months</time_frame>
    <description>Outcome 1 is the rate of device and/or procedure-related serious adverse events with onset within 7-days of any ablation procedure that uses the TactiFlex SE catheter (initial or repeat procedure performed 31-80 days of initial procedure) that are defined below:&#xD;
Atrio-esophageal fistula&#xD;
Cardiac tamponade/perforation&#xD;
Death&#xD;
Heart block&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve injury resulting in diaphragmatic paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke/cerebrovascular accident&#xD;
Thromboembolism&#xD;
Transient ischemic attack&#xD;
Vagal nerve injury/gastroparesis&#xD;
Vascular access complications (including major bleeding events)&#xD;
Atrio-esophageal fistula, cardiac tamponade/perforation and pulmonary vein stenosis will be evaluated through 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of freedom from atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT) recurrence</measure>
    <time_frame>Through 12 months</time_frame>
    <description>Outcome 2 for this clinical trial is freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of &gt;30 seconds duration that are documented by 12-lead ECG, transtelephonic monitoring (TTM) or Holter monitor after the initial catheter ablation procedure through 12-months of follow-up (9 months after a 90-day blanking period).&#xD;
AF/AFL/AT recurrence during the 90-day blanking period (≤90 days post-initial procedure) will not be considered a treatment failure. One repeat procedure will be allowed for ablation of AF/AFL/AT recurrence 31-80 days after the initial procedure and will not be considered a treatment failure. Failure to achieve acute procedural success during the last ablation procedure with the TactiFlex SE catheter will constitute failure. After the 90-day blanking period, use of Class I or III AADs will not count as a therapy failure provided that only previously failed Class I or III AADs are taken at doses that do not exceed the previously failed dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of freedom from atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT) recurrence, without AADs</measure>
    <time_frame>Through 12 months</time_frame>
    <description>Outcome 3 for this clinical trial is freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of &gt;30 seconds duration that are documented by 12-lead ECG, transtelephonic monitoring (TTM) or Holter monitor after the initial catheter ablation procedure through 12-months of follow-up (9 months after a 90-day blanking period).&#xD;
AF/AFL/AT recurrence during the 90-day blanking period (≤90 days post-initial procedure) will not be considered a treatment failure. One repeat procedure will be allowed for ablation of AF/AFL/AT recurrence 31-80 days after the initial procedure and will not be considered a treatment failure. Failure to achieve acute procedural success during the last ablation procedure with the TactiFlex SE catheter will constitute failure. After the 90-day blanking period, any use of a Class I or III AAD will count as an effectiveness failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of freedom from atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT) recurrence with only 1 ablation procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome 4 for this clinical trial is freedom from documented (symptomatic or asymptomatic) AF/AFL/AT episodes of &gt;30 seconds duration that are documented by 12-lead ECG, transtelephonic monitoring (TTM) or Holter monitor after the initial catheter ablation procedure through 12-months of follow-up (9 months after a 90-day blanking period).&#xD;
AF/AFL/AT recurrence during the 90-day blanking period (≤90 days post-initial procedure) will not be considered a treatment failure. Any repeat ablation procedure in the left atrium will be considered a treatment failure. Failure to achieve acute procedural success during the ablation procedure with the TactiFlex SE catheter will constitute failure. After the 90-day blanking period, use of Class I or III AADs will not count as a therapy failure provided that only previously failed Class I or III AADs are taken at doses that do not exceed the previously failed dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of freedom from symptomatic atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT) recurrence</measure>
    <time_frame>Through 12 months</time_frame>
    <description>Outcome 5 for this clinical trial is freedom from documented symptomatic AF/AFL/AT episodes of &gt;30 seconds duration that are documented by 12-lead ECG, transtelephonic monitoring (TTM) or Holter monitor after the initial catheter ablation procedure through 12-months of follow-up (9 months after a 90-day blanking period).&#xD;
AF/AFL/AT recurrence during the 90-day blanking period (≤90 days post-initial procedure) will not be considered a treatment failure. One repeat procedure will be allowed for ablation of AF/AFL/AT recurrence 31-80 days after the initial procedure and will not be considered a treatment failure. Failure to achieve acute procedural success during the last ablation procedure with the TactiFlex SE catheter will constitute failure. After the 90-day blanking period, use of Class I or III AADs will not count as a therapy failure provided that only previously failed Class I or III AADs are taken at doses that do not exceed the previously failed dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">355</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Main Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSP Sub-Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiFlex SE</intervention_name>
    <description>Radiofrequency ablation with the TactiFlex SE ablation catheter to treat paroxysmal AF. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.</description>
    <arm_group_label>Main Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiFlex SE - HSP</intervention_name>
    <description>Radiofrequency ablation with the TactiFlex SE ablation catheter to treat paroxysmal AF. Subjects in the HSP Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.</description>
    <arm_group_label>HSP Sub-Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A patient will be eligible for clinical trial participation if he/she meets the following&#xD;
        criteria:&#xD;
&#xD;
          1. Plans to undergo a catheter ablation procedure due to symptomatic PAF that is&#xD;
             refractory or intolerant to at least one Class I or III antiarrhythmic drug.&#xD;
&#xD;
          2. Physician's note indicating recurrent self-terminating AF&#xD;
&#xD;
          3. One electrocardiographically documented AF episode within 6-months prior to the&#xD;
             initial ablation procedure.&#xD;
&#xD;
          4. At least 18 years of age&#xD;
&#xD;
          5. Able and willing to comply with all trial requirements&#xD;
&#xD;
          6. Informed of the nature of the trial, agreed to its provisions and has provided written&#xD;
             informed consent as approved by the Institutional Review Board/Ethics Committee&#xD;
             (IRB/EC) of the respective clinical trial site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient will be excluded from enrollment in the clinical trial if he/she meets any of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Persistent or long-standing persistent atrial fibrillation&#xD;
&#xD;
          2. Active systemic infection&#xD;
&#xD;
          3. Known presence of cardiac thrombus&#xD;
&#xD;
          4. Hypertrophic cardiomyopathy&#xD;
&#xD;
          5. Arrhythmia due to reversible causes including thyroid disorders, acute alcohol&#xD;
             intoxication, and other major surgical procedures in the 90-day period preceding&#xD;
             procedure&#xD;
&#xD;
          6. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary&#xD;
             intervention (PCI), or valve or coronary bypass grafting surgery within 90 days of&#xD;
             procedure&#xD;
&#xD;
          7. Left atrial diameter &gt; 5.0 cm measured within 180 days of procedure (echocardiography&#xD;
             or CT)&#xD;
&#xD;
          8. Left ventricular ejection fraction &lt; 35% measured within 180 days of procedure&#xD;
             (echocardiography or CT)&#xD;
&#xD;
          9. New York Heart Association (NYHA) class III or IV&#xD;
&#xD;
         10. Previous left atrial surgical or catheter ablation procedure&#xD;
&#xD;
         11. Left atrial surgical procedure or incision with resulting scar (including LAA closure&#xD;
             device)&#xD;
&#xD;
         12. Previous tricuspid or mitral valve replacement or repair&#xD;
&#xD;
         13. Heart disease in which corrective surgery is anticipated within 180 days after the&#xD;
             procedure&#xD;
&#xD;
         14. Bleeding diathesis or suspected pro-coagulant state&#xD;
&#xD;
         15. Contraindication to long term anti-thromboembolic therapy&#xD;
&#xD;
         16. Presence of any condition that precludes appropriate vascular access&#xD;
&#xD;
         17. Renal failure requiring dialysis&#xD;
&#xD;
         18. Known sensitivity to contrast media (if needed during the procedure) that cannot be&#xD;
             controlled with pre-medication&#xD;
&#xD;
         19. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic&#xD;
             obstructive pulmonary disease) or any other disease or malfunction of the lungs or&#xD;
             respiratory system that produces severe chronic symptoms&#xD;
&#xD;
         20. Women who are pregnant or breastfeeding&#xD;
&#xD;
         21. Presence of other anatomic or comorbid condition that, in the investigator's opinion,&#xD;
             could limit the patient's ability to participate in the clinical trial or to comply&#xD;
             with follow up requirements, or impact the scientific soundness of the clinical trial&#xD;
             results&#xD;
&#xD;
         22. Patient is currently participating in another clinical trial or has participated in a&#xD;
             clinical trial within 30 days prior to screening that may interfere with this clinical&#xD;
             trial&#xD;
&#xD;
         23. Patient is unlikely to survive the protocol follow up period of 12-months after the&#xD;
             procedure&#xD;
&#xD;
         24. Body mass index &gt; 40 kg/m2&#xD;
&#xD;
         25. Presence of other medical, social, or psychological conditions that, in the&#xD;
             investigator's opinion, could limit the subject's ability to participate in the&#xD;
             clinical investigation or to comply with follow-up requirements, or impact the&#xD;
             scientific soundness of the clinical investigation results.&#xD;
&#xD;
         26. Individuals without legal authority&#xD;
&#xD;
         27. Individuals unable to read or write&#xD;
&#xD;
         28. Patients who have had a ventriculotomy or atriotomy within the preceding 4 weeks of&#xD;
             procedure,&#xD;
&#xD;
         29. Patients with prosthetic valves,&#xD;
&#xD;
         30. Patients with a myxoma,&#xD;
&#xD;
         31. Patients with an interatrial baffle or patch as the transseptal puncture could persist&#xD;
             and produce an iatrogenic atrial shunt&#xD;
&#xD;
         32. Patient unable to receive heparin or an acceptable alternative to achieve adequate&#xD;
             anticoagulation.&#xD;
&#xD;
         33. Stroke or TIA (transient ischemic attack) within the last 90 days&#xD;
&#xD;
         34. Stent, constriction, or stenosis in a pulmonary vein.&#xD;
&#xD;
         35. Rheumatic heart disease&#xD;
&#xD;
         36. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥&#xD;
             50%, and/or effective regurgitant orifice area ≥ 0.40cm2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Ruffner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Program Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Galoussian</last_name>
    <phone>818 493 2156</phone>
    <email>george.galoussian@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Sarver, PhD</last_name>
    <phone>651 756 3813</phone>
    <email>anne.sarver@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affinity Cardiovascular Specialists, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cooper</last_name>
    </contact>
    <investigator>
      <last_name>Gustavo Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Rubino</last_name>
    </contact>
    <investigator>
      <last_name>Devi Nair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Catherine Faulkner</last_name>
    </contact>
    <investigator>
      <last_name>Monica Lo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mills-Peninsula Medical Center</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Nava</last_name>
    </contact>
    <investigator>
      <last_name>Douglas Gibson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego (UCSD) Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Soltau</last_name>
    </contact>
    <investigator>
      <last_name>Sri Sundaram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Goodwin</last_name>
    </contact>
    <investigator>
      <last_name>Usman Siddiqui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Athens Regional Medical Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kootenai Heart Clinics</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Risk</last_name>
    </contact>
    <investigator>
      <last_name>Troy Hounshell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Bush</last_name>
    </contact>
    <investigator>
      <last_name>Rakesh Gopinathannair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Lunn</last_name>
    </contact>
    <investigator>
      <last_name>Michael Bernard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Edillo</last_name>
    </contact>
    <investigator>
      <last_name>Dipak Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Neal</last_name>
    </contact>
    <investigator>
      <last_name>Judson Colley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Gonzalez</last_name>
    </contact>
    <investigator>
      <last_name>Deepak Saluja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian Heywood</last_name>
    </contact>
    <investigator>
      <last_name>Sidharth Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Panko</last_name>
    </contact>
    <investigator>
      <last_name>Christine Tanaka-Esposito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianne Miller</last_name>
    </contact>
    <investigator>
      <last_name>Toshimasa Okabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandler Schwede</last_name>
    </contact>
    <investigator>
      <last_name>Michael Field</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Natale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Pierce</last_name>
    </contact>
    <investigator>
      <last_name>Saumya Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Barnett</last_name>
    </contact>
    <investigator>
      <last_name>Adam Shapira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Heart &amp; Vascular Associates</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fawna White</last_name>
    </contact>
    <investigator>
      <last_name>Eathar Razak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Wong</last_name>
    </contact>
    <investigator>
      <last_name>Saurabh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Private Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensl</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirt Myers</last_name>
    </contact>
    <investigator>
      <last_name>Deepak Arumugam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensl</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victori</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra O'Leary</last_name>
    </contact>
    <investigator>
      <last_name>Stewart Healy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5067</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Lin</last_name>
    </contact>
    <investigator>
      <last_name>Prash Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. ö. Krankenhaus der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <state>Upr Aus</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Steinkellner</last_name>
    </contact>
    <investigator>
      <last_name>Martin Reinhold Martinek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IKEM Prague</name>
      <address>
        <city>Prague</city>
        <state>Cbohmia</state>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Kuklova</last_name>
    </contact>
    <investigator>
      <last_name>Josef Kautzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabetes Zentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>N. Rhin</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bastian Grube</last_name>
    </contact>
    <investigator>
      <last_name>Philipp Sommer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>4289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Winkler</last_name>
    </contact>
    <investigator>
      <last_name>Sergio-Luis Richter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Ko</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sushanna Lai</last_name>
    </contact>
    <investigator>
      <last_name>Chin Pang Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Gulletta</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Della Bella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Thoraxcenter</name>
      <address>
        <city>Rotterdam</city>
        <state>S Holln</state>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (VGH)</name>
      <address>
        <city>Taipei</city>
        <state>Ntaiwan</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Ling Yao</last_name>
    </contact>
    <investigator>
      <last_name>Shih-Lin Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

